CMMB
Chemomab Therapeutics Ltd.
$2.27
+0.57 (+33.53%)
At close · Jul 2
Market Cap
$16.34M
Shares
575,381,320
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.27
Open$1.75
Day$1.75–2.42
52W$1.35–4.92
Avg vol 30d90K
Short int134K · 0.0% float · 2.7d
Short vol39%
Last earningsMay 11, 2023
DataJan 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+10% above
+
Price vs 50-day avg
+33% above
−
RSI (14)
74 · overbought
+
MACD trend
positive
◦
52-week position
26% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 200d above 50d
+
Institutional flow
+7% holders QoQ · +4 funds added
+
Insider flow
Net +$20.2K over 90 days · 0% sells
−
Short interest
0.02% of float · ▲ +247.4% MoM · 2.7 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
15 holders — 13F breadth
Fundamentals
Weak
−
EPS growth
−54% Y/Y
−
Free cash flow
$-11.1M
+
Balance sheet
net cash $7.6M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2023
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+10% above
Bullish
Price vs 50-day avg
+33% above
Bullish
RSI (14)
74 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
26% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+7% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$20.2K over 90 days · 0% sells
Short interest
Rising
0.02% of float · ▲ +247.4% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $1
Now $2 · 26%
52-wk high $5
vs 200-day avg +10%
vs 50-day avg +33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMMB
this stock
Chemomab Therapeutics Ltd.
|
$16.34M | +37.6% | — | — | 0.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
15
- % held
- 0.1%
- Net QoQ
- -15.8K sh
- Top holder
- ADAR1 Capital Management,…
Held
Float
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMMB | +45.5% | +32.0% | +26.1% | +40.1% | +37.6% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +44.1% | +33.2% | +18.1% | +40.4% | +28.4% |